All Content
Understand the changes of RDC 749 2022 in the pharmaceutical sector
RDC 749/2022 is the Resolution of the Collegiate Board, created by Anvisa to regulate the exemption of bioequivalence/bioavailability studies in producing new drugs — which is called biowaiver. After being published, this resolution led to the revocation of the former RDC 37/1 RDC 37/11. The main objective of the new RDC is to ensure the … Continue reading “Understand the changes of RDC 749 2022 in the pharmaceutical sector”
Read more